Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNN Imunon, Inc.

Not Yet Opened 12-18 16:00:00 EST

3.79

-0.08

-2.07%

盘后3.79

+0.000.00%

18:38 EST

High3.95	Low3.79	Vol32.22K
Open3.83	D1 Closing3.87	Amplitude4.07%
Mkt Cap11.64M	Tradable Cap11.51M	Total Shares3.07M
T/O123.55K	T/O Rate1.06%	Tradable Shares3.04M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMNN","market":"US","secType":"STK","nameCN":"Imunon, Inc.","latestPrice":3.79,"timestamp":1766091600000,"preClose":3.87,"halted":0,"volume":32224,"hourTrading":{"tag":"盘后","latestPrice":3.79,"preClose":3.79,"latestTime":"18:38 EST","volume":3,"amount":11.43,"timestamp":1766101131043},"delay":0,"floatShares":3036400,"shares":3070354,"eps":-13.473501,"marketStatus":"Not Yet Opened","change":-0.08,"latestTime":"12-18 16:00:00 EST","open":3.83,"high":3.9475,"low":3.79,"amount":123547.089904,"amplitude":0.040698,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.473501,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":0,"adr":0,"listingDate":959745600000,"exchange":"NASDAQ","adjPreClose":3.87,"postHourTrading":{"tag":"盘后","latestPrice":3.79,"preClose":3.79,"latestTime":"18:38 EST","volume":3,"amount":11.43,"timestamp":1766101131043},"volumeRatio":0.943127},"requestUrl":"/m/hq/s/IMNN/tweets","defaultTab":"tweets","newsList":[{"id":"2583665288","title":"Imunon, Inc. Faces Market Volatility: The Impact of Short Selling on Stock Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2583665288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583665288?lang=en_us&edition=fundamental","pubTime":"2025-11-16 14:01","pubTimestamp":1763272901,"startTime":"0","endTime":"0","summary":"Imunon, Inc. (IMNN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Imunon, Inc. faces a significant risk from market a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/imunon-inc-faces-market-volatility-the-impact-of-short-selling-on-stock-prices?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/imunon-inc-faces-market-volatility-the-impact-of-short-selling-on-stock-prices?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2583054575","title":"Alliance Global Partners Remains a Buy on Imunon (IMNN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583054575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583054575?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:35","pubTimestamp":1763123733,"startTime":"0","endTime":"0","summary":"In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on Imunon, with a price target of $12.00. According ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-remains-a-buy-on-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-remains-a-buy-on-imunon-imnn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583598329","title":"Corrected-Imunon Inc - Reports Q3 Loss per Share (Not 'EPS') $1.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598329?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:06","pubTimestamp":1763039213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL8N3WP13W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583756026","title":"Imunon reports Q3 EPS ($1.16) vs ($3.76) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2583756026","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583756026?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:50","pubTimestamp":1763038255,"startTime":"0","endTime":"0","summary":"“IMUNON (IMNN) is rapidly advancing a potential breakthrough for women with newly diagnosed advanced ovarian cancer-a disease with no meaningful fr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-reports-q3-eps-1-16-vs-3-76-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-reports-q3-eps-1-16-vs-3-76-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583560532","title":"Imunon Inc. reports third quarter net loss of $3.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560532","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560532?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:49","pubTimestamp":1763038157,"startTime":"0","endTime":"0","summary":"Imunon Inc. reported a net loss of $3.4 million, or $1.16 per share, for the third quarter of 2025, compared to a net loss of $4.8 million, or $3.8 per share, in the same period of 2024. Operating expenses were $3.5 million for the third quarter of 2025, down 30% from $5.0 million in the third quarter of 2024. During the period, Imunon advanced its Phase 3 clinical development of lead candidate IMNN-001 for newly diagnosed advanced ovarian cancer, expanded trial sites, and reported enrollment exceeding expectations. The company also presented translational data from the Phase 2 OVATION 2 study and continued to seek strategic partnerships to support its PlaCCine platform for vaccines and oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL4ntFXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583603455","title":"Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583603455","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583603455?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:46","pubTimestamp":1763037999,"startTime":"0","endTime":"0","summary":"Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48830942/imunon-q3-eps-1-16-beats-1-80-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2583560533","title":"Imunon Inc - Reports Q3 EPS $1.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560533?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:45","pubTimestamp":1763037900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA115TVB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2582765948","title":"Imunon Launches Phase 3 Trial of IMNN-001 Immunotherapy for Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582765948","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582765948?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:35","pubTimestamp":1762778154,"startTime":"0","endTime":"0","summary":"Imunon Inc. has announced updates on the clinical progress of its novel DNA-mediated immunotherapy, IMNN-001, for the treatment of newly diagnosed advanced ovarian cancer. The company is currently conducting a Phase 3 pivotal trial, OVATION 3, with site expansions and patient enrollment reportedly exceeding expectations. During an R&D Day event, Imunon presented new data from the Phase 2 OVATION 2 Study and a minimal residual disease  study, highlighting IMNN-001's impact on activating both innate and adaptive immune systems and remodeling the tumor microenvironment. The event included presentations from key opinion leaders and provided updates on clinical milestones, with additional results and materials made available via the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLVNDTw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2582187507","title":"Imunon R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women With Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582187507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582187507?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:30","pubTimestamp":1762777800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA2BHRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2581988118","title":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988118","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988118?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:54","pubTimestamp":1762527257,"startTime":"0","endTime":"0","summary":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview Imunon Inc IMNN.OQ IMNN.O is expected to  show no change in quarterly revenue when it reports  results on November 13 for the pe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ21N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2581088330","title":"BRIEF-Imunon Research And Development Day: Opportunity To Hear Clinical Trial Investigators Discuss Significant Potential Of IMNN-001 To Redefine Ovarian Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581088330","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581088330?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:12","pubTimestamp":1762521166,"startTime":"0","endTime":"0","summary":"BRIEF-Imunon Research And Development Day: Opportunity To Hear Clinical Trial Investigators Discuss Significant Potential Of IMNN-001 To Redefine Ovarian Cancer TreatmentNov 7 (Reuters) - Imunon Inc I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA171MKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2581887258","title":"Imunon R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of Imnn-001 to Redefine Ovarian Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887258?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:05","pubTimestamp":1762520700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA171MKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2580219307","title":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580219307","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580219307?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:01","pubTimestamp":1762178464,"startTime":"0","endTime":"0","summary":"Imunon Inc  expected to post a loss of $1.81 a share - Earnings Preview Imunon Inc IMNN.OQ IMNN.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimated)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2579268149","title":"IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579268149","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579268149?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:00","pubTimestamp":1761825600,"startTime":"0","endTime":"0","summary":"Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct.  30, 2025  (GLOBE NEWSWIRE) -- IMUNON, I","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177359/0/en/IMUNON-to-Present-Phase-3-OVATION-3-Study-of-IMNN-001-in-Advanced-Ovarian-Cancer-at-IGCS-2025-Annual-Global-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","PFS","BK4211","BK4139","BK4195","BK4097","OS"],"gpt_icon":0},{"id":"2577583925","title":"IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577583925","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577583925?lang=en_us&edition=fundamental","pubTime":"2025-10-23 22:01","pubTimestamp":1761228060,"startTime":"0","endTime":"0","summary":"IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct.  23, 2025  (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in P","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/23/3172179/0/en/IMUNON-to-Present-New-Translational-Data-from-Phase-2-OVATION-2-Study-of-IMNN-001-at-SITC-40th-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","01308","BK1103","BK4097","SITC","IE00BYQNZ168.SGD","BK4231","OS","IMNN","BK4139","BK1541","IE00BYTNYN87.SGD","ACT","IE00B12V2V27.USD","SG9999011746.SGD"],"gpt_icon":0},{"id":"2575218426","title":"Imunon to present Phase 3 OVATION trial of IMNN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2575218426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575218426?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:36","pubTimestamp":1760445403,"startTime":"0","endTime":"0","summary":"IMUNON (IMNN) announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-to-present-phase-3-ovation-trial-of-imnn-001-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-to-present-phase-3-ovation-trial-of-imnn-001-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2575529075","title":"IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2575529075","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575529075?lang=en_us&edition=fundamental","pubTime":"2025-10-14 20:20","pubTimestamp":1760444400,"startTime":"0","endTime":"0","summary":"Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on trac","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166173/0/en/IMUNON-to-Present-Phase-3-Ovarian-Cancer-Study-of-IMNN-001-at-ESMO-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OS","IMNN","BK4195","ACT","BK4229","BK4097"],"gpt_icon":0},{"id":"2569827217","title":"Imunon Inc. Releases Document on IL-12 Gene Therapy's Impact in Ovarian Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2569827217","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569827217?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:54","pubTimestamp":1758545673,"startTime":"0","endTime":"0","summary":"Imunon Inc. has published a document detailing the results of the OVATION-2 trial, which investigates the efficacy and safety of IMNN-001, an IL-12 gene therapy, in combination with Neo/Adjuvant chemotherapy for newly diagnosed epithelial ovarian cancer. The document outlines the observed improvements in progression-free survival  and overall survival  and discusses the immune effects of the therapy on the tumor microenvironment. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief on September 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL73JRYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMNN"],"gpt_icon":0},{"id":"2569078472","title":"Imunon: OVATION 2 study results reinforce IMNN-001 efficacy benefits","url":"https://stock-news.laohu8.com/highlight/detail?id=2569078472","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569078472?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:20","pubTimestamp":1758543643,"startTime":"0","endTime":"0","summary":"Imunon (IMNN) announced the presentation of new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational gene-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imunon-ovation-2-study-results-reinforce-imnn-001-efficacy-benefits-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imunon-ovation-2-study-results-reinforce-imnn-001-efficacy-benefits-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNN","BK4139"],"gpt_icon":0},{"id":"2569278263","title":"IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2569278263","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569278263?lang=en_us&edition=fundamental","pubTime":"2025-09-22 20:05","pubTimestamp":1758542700,"startTime":"0","endTime":"0","summary":"Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153898/0/en/IMUNON-Presents-IMNN-001-Phase-2-Translational-Data-in-Advanced-Ovarian-Cancer-Demonstrating-13-Month-OS-Extension-via-Tumor-Micro-Environment-Shift.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imunon.com","stockEarnings":[{"period":"1week","weight":-0.0823},{"period":"1month","weight":-0.0733},{"period":"3month","weight":-0.239},{"period":"6month","weight":-0.7151},{"period":"1year","weight":-0.6501},{"period":"ytd","weight":-0.6941}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.424242,"avgChangeRate":0.08883},{"month":2,"riseRate":0.375,"avgChangeRate":0.031658},{"month":3,"riseRate":0.515152,"avgChangeRate":0.050761},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.048439},{"month":5,"riseRate":0.352941,"avgChangeRate":0.12499},{"month":6,"riseRate":0.441176,"avgChangeRate":-0.05147},{"month":7,"riseRate":0.382353,"avgChangeRate":-0.054834},{"month":8,"riseRate":0.411765,"avgChangeRate":0.007426},{"month":9,"riseRate":0.294118,"avgChangeRate":-0.078238},{"month":10,"riseRate":0.294118,"avgChangeRate":-0.043613},{"month":11,"riseRate":0.294118,"avgChangeRate":-0.024039},{"month":12,"riseRate":0.441176,"avgChangeRate":-0.041552}],"exchange":"NASDAQ","name":"Imunon, Inc.","nameEN":"Imunon, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Imunon, Inc.,IMNN,Imunon, Inc.股票,Imunon, Inc.股票老虎,Imunon, Inc.股票老虎国际,Imunon, Inc.行情,Imunon, Inc.股票行情,Imunon, Inc.股价,Imunon, Inc.股市,Imunon, Inc.股票价格,Imunon, Inc.股票交易,Imunon, Inc.股票购买,Imunon, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Imunon, Inc.(IMNN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Imunon, Inc.(IMNN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction